Relief Therapeutics Holding SA announced the appointment of David McCullough as senior director and Head of U.S. Market Access, effective August 22, 2022. In this newly created position, reporting to Anthony Kim, Senior Vice President and Head of U.S. Commercial Operations, Mr. McCullough will direct Relief's market access strategy and operations to ensure timely and effective access to Relief's products for patients in the U.S. Prior to joining Relief, Mr. McCullough served as National Account Director (Payer Account Lead) at Mirum Pharmaceuticals Inc., a biopharmaceutical company focused on the treatment of rare diseases, where he was responsible for building out the company's Medicaid launch strategy and supporting the expansion of key market access policies. Previously, he held several positions of increasing responsibility at Novartis Gene Therapies (formerly AveXis), most recently, as Director National Accounts, where he was responsible for successfully negotiating multiple Value-Based Agreements and 10 state Medicaid policies.

Before that, he worked as a Patient Access Liaison at Spark Therapeutics, supporting the launch of a first-of-its-kind gene therapy in the inherited retinal disease space and also aided in the build-out of patient services and market access operations. Before Spark Therapeutics, Mr. McCullough was Associate Director, Patient Services Southeast at Shire. Earlier in his career, Mr. McCullough held numerous market access and commercial operations positions at various biotechnology and pharmaceutical companies, including an Institutional Specialty Manager at MedImmune and a Territory Manager at Abbott Laboratories.

Mr. McCullough earned a BA in Speech/Public Relations from McNeese State University, a BS in Ministry and Theology from St. Louis Christian College and served four years in the United States Coast Guard.